EXOCEL BIO Revenue and Competitors
Estimated Revenue & Valuation
- EXOCEL BIO's estimated annual revenue is currently $3.3M per year.
- EXOCEL BIO's estimated revenue per employee is $155,000
Employee Data
- EXOCEL BIO has 21 Employees.
- EXOCEL BIO grew their employee count by 5% last year.
EXOCEL BIO's People
Name | Title | Email/Phone |
---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Sr. Director - Strategy & Operations | Reveal Email/Phone |
3 | Territory Sales Manager | Reveal Email/Phone |
4 | Senior Business Development Manager | Reveal Email/Phone |
5 | Executive Chairman | Reveal Email/Phone |
6 | Practice Integration Specialist | Reveal Email/Phone |
7 | Principal Research Scientist | Reveal Email/Phone |
8 | Senior Account Executive | Reveal Email/Phone |
EXOCEL BIO Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is EXOCEL BIO?
EXOCEL BIO provides a platform of MSC-derived exosomes with the highest potency and safety profile, to drive the next generation of regenerative medicine. (NEXGEN REGENâ„¢). We aim at transforming the Regenerative Medicine space by deploying highly purified and concentrated nanoparticles providing higher safety and effectiveness than currently available therapies.
keywords:N/AN/A
Total Funding
21
Number of Employees
$3.3M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.1M | 21 | -9% | N/A |
#2 | $4M | 21 | -5% | N/A |
#3 | $2.1M | 21 | N/A | N/A |
#4 | $1.1M | 21 | N/A | N/A |
#5 | $3.3M | 21 | -12% | N/A |